Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2018 (2018), Article ID 9652897, 15 pages
https://doi.org/10.1155/2018/9652897
Review Article

The Potentials and Caveats of Mesenchymal Stromal Cell-Based Therapies in the Preterm Infant

1Department of General Pediatrics and Neonatology, Justus-Liebig-University, Feulgenstrasse 12, 35392 Gießen, Germany
2German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Feulgenstrasse 12, 35392 Gießen, Germany
3Excellence Cluster Cardio-Pulmonary System (ECCPS), German Center for Lung Research (DZL), Department of Internal Medicine II, Universities of Giessen and Marburg Lung Center (UGMLC), Aulweg 130, 35392 Giessen, Germany
4Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, German Center Lung Research (DZL), 61231 Bad Nauheim, Germany
5Division of Neonatology, Perinatal Center, University Children’s Hospital, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, 81377 Munich, Germany

Correspondence should be addressed to Harald Ehrhardt; ed.nesseig-inu.dem.taideap@tdrahrhe.dlarah

Received 9 August 2017; Accepted 4 March 2018; Published 8 April 2018

Academic Editor: Suk Ying TSANG

Copyright © 2018 Judith Gronbach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Max Planck.

Linked References

  1. L. da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, “Mesenchymal stem cells reside in virtually all post-natal organs and tissues,” Journal of Cell Science, vol. 119, no. 11, pp. 2204–2213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. E. El Agha, R. Kramann, R. K. Schneider et al., “Mesenchymal stem cells in fibrotic disease,” Cell Stem Cell, vol. 21, no. 2, pp. 166–177, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Bancalari and A. Gonzalez, “Clinical course and lung function abnormalities during development of neonatal chronic lung disease,” in Chronic Lung Disease in Early Infancy, R. D. Bland and J. J. Coalson, Eds., pp. 41–64, Marcel Dekker, New York City, NY, USA, 2000. View at Google Scholar
  5. L. Gortner, B. Misselwitz, D. Milligan et al., “Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort,” Neonatology, vol. 99, no. 2, pp. 112–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. H. Jobe and E. Bancalari, “Bronchopulmonary dysplasia,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 7, pp. 1723–1729, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Ehrenkranz, M. C. Walsh, B. R. Vohr et al., “Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia,” Pediatrics, vol. 116, no. 6, pp. 1353–1360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. W. Doyle, B. Faber, C. Callanan, N. Freezer, G. W. Ford, and N. M. Davis, “Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence,” Pediatrics, vol. 118, no. 1, pp. 108–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Didon, A. B. Roos, G. P. Elmberger, F. J. Gonzalez, and M. Nord, “Lung-specific inactivation of CCAAT/enhancer binding protein α causes a pathological pattern characteristic of COPD,” European Respiratory Journal, vol. 35, no. 1, pp. 186–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Wood, K. Costeloe, A. T. Gibson et al., “The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth,” Archives of Disease in Childhood-Fetal and Neonatal Edition, vol. 90, no. 2, pp. F134–F140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. P. M. Lavoie, C. Pham, and K. L. Jang, “Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the National Institutes of Health,” Pediatrics, vol. 122, no. 3, pp. 479–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Shahzad, S. Radajewski, C.-M. Chao, S. Bellusci, and H. Ehrhardt, “Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development,” Molecular and Cellular Pediatrics, vol. 3, no. 1, p. 23, 2016. View at Publisher · View at Google Scholar
  13. V. Compernolle, K. Brusselmans, T. Acker et al., “Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice,” Nature Medicine, vol. 8, no. 7, pp. 702–710, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Weichelt, R. Cay, T. Schmitz et al., “Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine,” European Respiratory Journal, vol. 41, no. 4, pp. 966–973, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Hilgendorff, I. Reiss, H. Ehrhardt, O. Eickelberg, and C. M. Alvira, “Chronic lung disease in the preterm infant. Lessons learned from animal models,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Oak, T. Pritzke, I. Thiel et al., “Attenuated PDGF signaling drives alveolar and microvascular defects in neonatal chronic lung disease,” EMBO Molecular Medicine, vol. 9, no. 11, pp. 1504–1520, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. W. H. Northway Jr, R. C. Rosan, and D. Y. Porter, “Pulmonary disease following respirator therapy of hyaline-membrane disease — bronchopulmonary dysplasia,” The New England Journal of Medicine, vol. 276, no. 7, pp. 357–368, 1967. View at Publisher · View at Google Scholar · View at Scopus
  18. K. R. Stenmark and S. H. Abman, “Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia,” Annual Review of Physiology, vol. 67, no. 1, pp. 623–661, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. P. Popova, J. Kelley Bentley, A. C. Anyanwu et al., “Glycogen synthase kinase-3β/β-catenin signaling regulates neonatal lung mesenchymal stromal cell myofibroblastic differentiation,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 303, no. 5, pp. L439–L448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. T. J. Witsch, G. Niess, E. Sakkas et al., “Transglutaminase 2: a new player in bronchopulmonary dysplasia?” European Respiratory Journal, vol. 44, no. 1, pp. 109–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. T. J. Witsch, P. Turowski, E. Sakkas et al., “Deregulation of the lysyl hydroxylase matrix cross-linking system in experimental and clinical bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 306, no. 3, pp. L246–L259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. K. H. Albertine, G. P. Jones, B. C. STarcher et al., “Chronic lung injury in preterm lambs: disordered respiratory tract development,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 3, pp. 945–958, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. P. D. Bozyk, A. P. Popova, J. K. Bentley et al., “Mesenchymal stromal cells from neonatal tracheal aspirates demonstrate a pattern of lung-specific gene expression,” Stem Cells and Development, vol. 20, no. 11, pp. 1995–2007, 2011. View at Publisher · View at Google Scholar
  24. H. Boström, K. Willetts, M. Pekny et al., “PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis,” Cell, vol. 85, no. 6, pp. 863–873, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Ehrhardt, T. Pritzke, P. Oak et al., “Absence of TNF-α enhances inflammatory response in the newborn lung undergoing mechanical ventilation,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 310, no. 10, pp. L909–L918, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Ahlfeld and S. J. Conway, “Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia,” Birth Defects Research Part A: Clinical and Molecular Teratology, vol. 94, no. 1, pp. 3–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-M. Chao, E. El Agha, C. Tiozzo, P. Minoo, and S. Bellusci, “A breath of fresh air on the mesenchyme: impact of impaired mesenchymal development on the pathogenesis of bronchopulmonary dysplasia,” Frontiers in Medicine, vol. 2, 2015. View at Publisher · View at Google Scholar
  28. J. Gauldie, T. Galt, P. Bonniaud, C. Robbins, M. Kelly, and D. Warburton, “Transfer of the active form of transforming growth factor-β1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia,” The American Journal of Pathology, vol. 163, no. 6, pp. 2575–2584, 2003. View at Publisher · View at Google Scholar
  29. P. Bonniaud, M. Kolb, T. Galt et al., “Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis,” The Journal of Immunology, vol. 173, no. 3, pp. 2099–2108, 2004. View at Publisher · View at Google Scholar
  30. T. S. Blackwell, A. N. Hipps, Y. Yamamoto et al., “NF-κB signaling in fetal lung macrophages disrupts airway morphogenesis,” The Journal of Immunology, vol. 187, no. 5, pp. 2740–2747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Iosef, T.-P. Alastalo, Y. Hou et al., “Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarization,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 302, no. 10, pp. L1023–L1036, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S. McKenna, K. A. Michaelis, F. Agboke et al., “Sustained hyperoxia-induced NF-κB activation improves survival and preserves lung development in neonatal mice,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 306, no. 12, pp. L1078–L1089, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Hou, M. Liu, C. Husted et al., “Activation of the nuclear factor-κB pathway during postnatal lung inflammation preserves alveolarization by suppressing macrophage inflammatory protein-2,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 309, no. 6, pp. L593–L604, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Y. Ahn, Y. S. Chang, and W. S. Park, “Mesenchymal stem cells transplantation for neuroprotection in preterm infants with severe intraventricular hemorrhage,” Korean journal of pediatrics, vol. 57, no. 6, pp. 251–256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. E. Hartnett and J. S. Penn, “Mechanisms and management of retinopathy of prematurity,” The New England Journal of Medicine, vol. 367, no. 26, pp. 2515–2526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. P. C. Ng, “Biomarkers of necrotising enterocolitis,” Seminars in Fetal & Neonatal Medicine, vol. 19, no. 1, pp. 33–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Hodzic, A. M. Bolock, and M. Good, “The role of mucosal immunity in the pathogenesis of necrotizing enterocolitis,” Frontiers in Pediatrics, vol. 5, p. 40, 2017. View at Publisher · View at Google Scholar
  38. A. M. Nuyt, J.-C. Lavoie, I. Mohamed, K. Paquette, and T. M. Luu, “Adult consequences of extremely preterm birth: cardiovascular and metabolic diseases risk factors, mechanisms, and prevention avenues,” Clinics in Perinatology, vol. 44, no. 2, pp. 315–332, 2017. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Tare, J. G. Bensley, T. J. M. Moss et al., “Exposure to intrauterine inflammation leads to impaired function and altered structure in the preterm heart of fetal sheep,” Clinical Science, vol. 127, no. 9, pp. 559–569, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. B. J. Stoll, N. I. Hansen, E. F. Bell et al., “Neonatal outcomes of extremely preterm infants from the NICHD neonatal research network,” Pediatrics, vol. 126, no. 3, pp. 443–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. R. Alexander and M. Slay, “Prematurity at birth: trends, racial disparities, and epidemiology,” Developmental Disabilities Research Reviews, vol. 8, no. 4, pp. 215–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. B. J. Stoll, N. I. Hansen, E. F. Bell et al., “Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012,” JAMA, vol. 314, no. 10, pp. 1039–1051, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. C. T. McEvoy, L. Jain, B. Schmidt, S. Abman, E. Bancalari, and J. L. Aschner, “Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases,” Annals of the American Thoracic Society, vol. 11, Supplement 3, pp. S146–S153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. K. S. Beam, S. Aliaga, S. K. Ahlfeld, M. Cohen-Wolkowiez, P. B. Smith, and M. M. Laughon, “A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants,” Journal of perinatology, vol. 34, no. 9, pp. 705–710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Sanchez-Solis, V. Perez-Fernandez, V. Bosch-Gimenez, J. J. Quesada, and L. Garcia-Marcos, “Lung function gain in preterm infants with and without bronchopulmonary dysplasia,” Pediatric Pulmonology, vol. 51, no. 9, pp. 936–942, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. K. J. Barrington, “The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs,” BMC Pediatrics, vol. 1, no. 1, p. 1, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Gao, S. M. Chiu, D. A. L. Motan et al., “Mesenchymal stem cells and immunomodulation: current status and future prospects,” Cell Death & Disease, vol. 7, no. 1, article e2062, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. J. J. Collins and B. Thébaud, “Lung mesenchymal stromal cells in development and disease: to serve and protect?” Antioxidants & redox signaling, vol. 21, no. 13, pp. 1849–1862, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Rohban and T. R. Pieber, “Mesenchymal stem and progenitor cells in regeneration: tissue specificity and regenerative potential,” Stem Cells International, vol. 2017, Article ID 5173732, 16 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. Kumar, P. E. Bogard, F. Hernán Espinoza, D. B. Menke, D. M. Kingsley, and M. A. Krasnow, “Defining a mesenchymal progenitor niche at single-cell resolution,” Science, vol. 346, no. 6211, article 1258810, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. K. U. Hong, S. D. Reynolds, S. Watkins, E. Fuchs, and B. R. Stripp, “In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 286, no. 4, pp. L643–L649, 2004. View at Publisher · View at Google Scholar
  52. K. U. Hong, S. D. Reynolds, S. Watkins, E. Fuchs, and B. R. Stripp, “Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium,” The American Journal of Pathology, vol. 164, no. 2, pp. 577–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Giangreco, H. Shen, S. D. Reynolds, and B. R. Stripp, “Molecular phenotype of airway side population cells,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 286, no. 4, pp. L624–L630, 2004. View at Publisher · View at Google Scholar
  54. R. Reddy, S. Buckley, M. Doerken et al., “Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 286, no. 4, pp. L658–L667, 2004. View at Publisher · View at Google Scholar
  55. J. Kajstura, M. Rota, S. R. Hall et al., “Evidence for human lung stem cells,” The New England Journal of Medicine, vol. 364, no. 19, pp. 1795–1806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Irwin, K. Helm, N. Campbell et al., “Neonatal lung side population cells demonstrate endothelial potential and are altered in response to hyperoxia-induced lung simplification,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 293, no. 4, pp. L941–L951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Balasubramaniam, C. F. Mervis, A. M. Maxey, N. E. Markham, and S. H. Abman, “Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 292, no. 5, pp. L1073–L1084, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. C. D. Baker, V. Balasubramaniam, P. M. Mourani et al., “Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia,” European Respiratory Journal, vol. 40, no. 6, pp. 1516–1522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. C. D. Baker, S. L. Ryan, D. A. Ingram, G. J. Seedorf, S. H. Abman, and V. Balasubramaniam, “Endothelial colony-forming cells from preterm infants are increased and more susceptible to hyperoxia,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 454–461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Borghesi, M. Massa, R. Campanelli et al., “Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 6, pp. 540–546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. C. D. Baker, G. J. Seedorf, B. L. Wisniewski et al., “Endothelial colony-forming cell conditioned media promote angiogenesis in vitro and prevent pulmonary hypertension in experimental bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 305, no. 1, pp. L73–L81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Balasubramaniam, S. L. Ryan, G. J. Seedorf et al., “Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 298, no. 3, pp. L315–L323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. R. S. Alphonse, A. Vadivel, M. Fung et al., “Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth,” Circulation, vol. 129, no. 21, pp. 2144–2157, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. M. A. Möbius and M. Rüdiger, “Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia,” Molecular and Cellular Pediatrics, vol. 3, no. 1, p. 18, 2016. View at Publisher · View at Google Scholar
  65. P. R. Amable, M. V. Teixeira, R. B. Carias, J. Granjeiro, and R. Borojevic, “Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly,” Stem Cell Research & Therapy, vol. 5, no. 2, p. 53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. C. M. Chao, F. Yahya, A. Moiseenko et al., “Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia,” The Journal of Pathology, vol. 241, no. 1, pp. 91–103, 2017. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Moiseenko, V. Kheirollahi, C. M. Chao et al., “Origin and characterization of alpha smooth muscle actin-positive cells during murine lung development,” Stem Cells, vol. 35, no. 6, pp. 1566–1578, 2017. View at Publisher · View at Google Scholar · View at Scopus
  68. D. M. Silva, C. Nardiello, A. Pozarska, and R. E. Morty, “Recent advances in the mechanisms of lung alveolarization and the pathogenesis of bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 309, no. 11, pp. L1239–L1272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Ruiz-Camp and R. E. Morty, “Divergent fibroblast growth factor signaling pathways in lung fibroblast subsets: where do we go from here?” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 309, no. 8, pp. L751–L755, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Le Blanc, “Mesenchymal stromal cells: tissue repair and immune modulation,” Cytotherapy, vol. 8, no. 6, pp. 559–561, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. N. G. Singer and A. I. Caplan, “Mesenchymal stem cells: mechanisms of inflammation,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, no. 1, pp. 457–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Fujinaga, C. D. Baker, S. L. Ryan et al., “Hyperoxia disrupts vascular endothelial growth factor-nitric oxide signaling and decreases growth of endothelial colony-forming cells from preterm infants,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 297, no. 6, pp. L1160–L1169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. P. F. Vassallo, S. Simoncini, I. Ligi et al., “Accelerated senescence of cord blood endothelial progenitor cells in premature neonates is driven by SIRT1 decreased expression,” Blood, vol. 123, no. 13, pp. 2116–2126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. T. van Haaften, R. Byrne, S. Bonnet et al., “Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 11, pp. 1131–1142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Shakibaei, P. Shayan, F. Busch et al., “Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation,” PLoS One, vol. 7, no. 4, article e35712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. H.-F. Yuan, C. Zhai, X. L. Yan et al., “SIRT1 is required for long-term growth of human mesenchymal stem cells,” Journal of Molecular Medicine, vol. 90, no. 4, pp. 389–400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Minagawa, J. Araya, T. Numata et al., “Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 300, no. 3, pp. L391–L401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. O. Khwaja and J. Volpe, “Pathogenesis of cerebral white matter injury of prematurity,” Archives of Disease in Childhood-Fetal and Neonatal Edition, vol. 93, no. 2, pp. F153–F161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. K. T. Hennrick, A. G. Keeton, S. Nanua et al., “Lung cells from neonates show a mesenchymal stem cell phenotype,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 11, pp. 1158–1164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Dominici, K. le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Reicherzer, S. Häffner, T. Shahzad et al., “Pro-inflammatory NFκB activation alters the phenotype of tracheal aspirate MSC in preterm infants developing severe BPD,” AJP LUNG, 2018. View at Google Scholar
  82. A. L. Ponte, E. Marais, N. Gallay et al., “The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities,” Stem Cells, vol. 25, no. 7, pp. 1737–1745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. A. P. Popova, P. D. Bozyk, A. M. Goldsmith et al., “Autocrine production of TGF-β1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 298, no. 6, pp. L735–L743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. A. P. Popova, J. K. Bentley, T. X. Cui et al., “Reduced platelet-derived growth factor receptor expression is a primary feature of human bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 307, no. 3, pp. L231–L239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Zhang, J. Fang, H. Su et al., “Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats,” Pediatric Transplantation, vol. 16, no. 6, pp. 589–598, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Luan, W. Ding, Z.-Y. Ju, Z.-H. Zhang, X. Zhang, and F. Kong, “Bone marrow-derived mesenchymal stem cells protect against lung injury in a mouse model of bronchopulmonary dysplasia,” Molecular Medicine Reports, vol. 11, no. 3, pp. 1945–1950, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Zhang, J. Fang, Y. Wu, Y. Mai, W. Lai, and H. Su, “Mesenchymal stem cells protect against neonatal rat hyperoxic lung injury,” Expert Opinion on Biological Therapy, vol. 13, no. 6, pp. 817–829, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Waszak, R. Alphonse, A. Vadivel, L. Ionescu, F. Eaton, and B. Thébaud, “Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats,” Stem Cells and Development, vol. 21, no. 15, pp. 2789–2797, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Aslam, R. Baveja, O. D. Liang et al., “Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 11, pp. 1122–1130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. S. Chang, S. J. Choi, D. K. Sung et al., “Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats,” Cell Transplantation, vol. 20, no. 11-12, pp. 1843–1854, 2011. View at Google Scholar
  91. Y. S. Chang, W. Oh, S. J. Choi et al., “Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats,” Cell Transplantation, vol. 18, no. 8, pp. 869–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Y. Ahn, Y. S. Chang, J. H. Kim, S. I. Sung, and W. S. Park, “Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia,” The Journal of Pediatrics, vol. 185, pp. 49–54.e2, 2017. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Y. Ahn, Y. S. Chang, S. Y. Kim et al., “Long-term (postnatal day 70) outcome and safety of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells in neonatal hyperoxic lung injury,” Yonsei Medical Journal, vol. 54, no. 2, pp. 416–424, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. S. Chang, S. Y. Ahn, H. S. Yoo et al., “Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial,” The Journal of pediatrics, vol. 164, no. 5, pp. 966–972.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Zhu, E. M. Wallace, and R. Lim, “Cell-based therapies for the preterm infant,” Cytotherapy, vol. 16, no. 12, pp. 1614–1628, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. M. E. Fung and B. Thébaud, “Stem cell–based therapy for neonatal lung disease: it is in the juice,” Pediatric Research, vol. 75, no. 1-1, pp. 2–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. Z. Tian, J. du, B. Wang, X. Y. Hong, and Z. C. Feng, “Intravenous infusion of rat bone marrow-derived mesenchymal stem cells ameliorates hyperoxia-induced lung injury in neonatal rats,” Nan fang yi ke da xue xue bao=Journal of Southern Medical University, vol. 27, no. 11, pp. 1692–1695, 2007. View at Google Scholar
  98. Z. Tian, J. Du, X. M. Fu, B. Wang, X. Y. Hong, and Z. C. Feng, “Influence of human bone marrow-derived mesenchymal stem cells on the lung of newborn rats damaged by hyperoxia,” Zhonghua er ke za zhi= Chinese journal of pediatrics, vol. 46, no. 1, pp. 4–8, 2008. View at Google Scholar
  99. G. Hansmann, A. Fernandez-Gonzalez, M. Aslam et al., “Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension,” Pulmonary circulation, vol. 2, no. 2, pp. 170–181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. R. P. Sutsko, K. C. Young, A. Ribeiro et al., “Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury,” Pediatric Research, vol. 73, no. 1, pp. 46–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. K. A. Tropea, E. Leder, M. Aslam et al., “Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 302, no. 9, pp. L829–L837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. X. Zhang, H. Wang, Y. Shi et al., “Role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newborn mice,” Cell Biology International, vol. 36, no. 6, pp. 589–594, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Gülaşı, A. Atıcı, Ş. N. Yılmaz et al., “Mesenchymal stem cell treatment in hyperoxia-induced lung injury in newborn rats,” Pediatrics International, vol. 58, no. 3, pp. 206–213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. S. Chang, S. J. Choi, S. Y. Ahn et al., “Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury,” PLoS One, vol. 8, no. 1, article e52419, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Pierro, L. Ionescu, T. Montemurro et al., “Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia,” Thorax, vol. 68, no. 5, pp. 475–484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. H.-C. Chou, Y.-T. Li, and C.-M. Chen, “Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia,” American Journal of Translational Research, vol. 8, no. 2, pp. 342–353, 2016. View at Google Scholar
  107. D. Monz, E. Tutdibi, C. Mildau et al., “Human umbilical cord blood mononuclear cells in a double-hit model of bronchopulmonary dysplasia in neonatal mice,” PLoS One, vol. 8, no. 9, article e74740, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. D. K. Sung, Y. S. Chang, S. Y. Ahn et al., “Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology,” PLoS One, vol. 10, no. 8, article e0135574, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. Y. S. Chang, S. Y. Ahn, H. B. Jeon et al., “Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury,” American Journal of Respiratory Cell and Molecular Biology, vol. 51, no. 3, pp. 391–399, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. R. L. Morton, D. Iklé, and C. W. White, “Loss of lung mitochondrial aconitase activity due to hyperoxia in bronchopulmonary dysplasia in primates,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 274, no. 1, pp. L127–L133, 1998. View at Publisher · View at Google Scholar
  111. V. Ratner, A. Starkov, D. Matsiukevich, R. A. Polin, and V. S. Ten, “Mitochondrial dysfunction contributes to alveolar developmental arrest in hyperoxia-exposed mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 5, pp. 511–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. C. Y. Lee, R. Kim, O. Ham et al., “Therapeutic potential of stem cells strategy for cardiovascular diseases,” Stem Cells International, vol. 2016, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Roubeix, A. Denoyer, F. Brignole-Baudouin, and C. Baudouin, “Mesenchymal stem cell therapy, a new hope for eye disease,” Journal francais d'ophtalmologie, vol. 38, no. 8, pp. 764–775, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. G. Dothel, E. Raschi, R. Rimondini, and F. de Ponti, “Mesenchymal stromal cell-based therapy: regulatory and translational aspects in gastroenterology,” World Journal of Gastroenterology, vol. 22, no. 41, pp. 9057–9068, 2016. View at Publisher · View at Google Scholar · View at Scopus
  115. C. T. van Velthoven, M. Dzietko, M. F. Wendland et al., “Mesenchymal stem cells attenuate MRI-identifiable injury, protect white matter, and improve long-term functional outcomes after neonatal focal stroke in rats,” Journal of Neuroscience Research, vol. 95, no. 5, pp. 1225–1236, 2017. View at Publisher · View at Google Scholar · View at Scopus
  116. C. T. van Velthoven, R. A. Sheldon, A. Kavelaars et al., “Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke,” Stroke, vol. 44, no. 5, pp. 1426–1432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. C. T. van Velthoven et al., “Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in mice,” Annals of Neurology, vol. 71, no. 6, pp. 785–796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. C. T. van Velthoven, A. Kavelaars, F. van Bel, and C. J. Heijnen, “Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain,” Brain, Behavior, and Immunity, vol. 25, no. 7, pp. 1342–1348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. C. T. Van Velthoven, A. Kavelaars, F. van Bel, and C. J. Heijnen, “Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage,” Pediatric Research, vol. 68, pp. 1–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. E. S. Kim, S. Y. Ahn, G. H. Im et al., “Human umbilical cord blood–derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats,” Pediatric Research, vol. 72, no. 3, pp. 277–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. W. S. Park, S. In Sung, S. Y. Ahn et al., “Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy,” PLoS One, vol. 10, no. 3, article e0120893, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Y. Ahn, Y. S. Chang, D. K. Sung et al., “Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage,” Stroke, vol. 44, no. 2, pp. 497–504, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Y. Ahn, Y. S. Chang, D. K. Sung et al., “Optimal route for mesenchymal stem cells transplantation after severe intraventricular hemorrhage in newborn rats,” PLoS One, vol. 10, no. 7, article e0132919, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Y. Ahn, Y. S. Chang, D. K. Sung, S. I. Sung, J. Y. Ahn, and W. S. Park, “Pivotal role of brain derived neurotrophic factor secreted by mesenchymal stem cells in severe intraventricular hemorrhage in the newborn rats,” Cell Transplantation, vol. 26, no. 1, pp. 145–156, 2016. View at Publisher · View at Google Scholar · View at Scopus
  125. V. Donega, C. H. Nijboer, C. T. J. van Velthoven et al., “Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse,” Pediatric Research, vol. 78, no. 5, pp. 520–526, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. A. M. Comi, E. Cho, J. D. Mulholland et al., “Neural stem cells reduce brain injury after unilateral carotid ligation,” Pediatric Neurology, vol. 38, no. 2, pp. 86–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. V. Donega, C. T. J. van Velthoven, C. H. Nijboer et al., “Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement,” PLoS One, vol. 8, no. 1, article e51253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. R. K. Jellema, T. G. A. M. Wolfs, V. Lima Passos et al., “Mesenchymal stem cells induce T-cell tolerance and protect the preterm brain after global hypoxia-ischemia,” PLoS One, vol. 8, no. 8, article e73031, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. N. Hoque, M. Thoresen, K. Aquilina, S. Hogan, and A. Whitelaw, “Decorin and colchicine as potential treatments for post-haemorrhagic ventricular dilatation in a neonatal rat model,” Neonatology, vol. 100, no. 3, pp. 271–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. C. T. van Velthoven, C. J. Heijnen, F. van Bel, and A. Kavelaars, “Osteopontin enhances endogenous repair after neonatal hypoxic–ischemic brain injury,” Stroke, vol. 42, no. 8, pp. 2294–2301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. K. Aquilina, C. Hobbs, A. Tucker, A. Whitelaw, and M. Thoresen, “Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?” Acta Paediatrica, vol. 97, no. 9, pp. 1181–1186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Aronowski and C. E. Hall, “New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies,” Neurological Research, vol. 27, no. 3, pp. 268–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Vinukonda, A. Csiszar, F. Hu et al., “Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition,” Brain, vol. 133, no. 8, pp. 2264–2280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. K. Dummula, G. Vinukonda, P. Chu et al., “Bone morphogenetic protein inhibition promotes neurological recovery after intraventricular hemorrhage,” The Journal of Neuroscience, vol. 31, no. 34, pp. 12068–12082, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Wang and S. E. Tsirka, “Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage,” Brain, vol. 128, no. 7, pp. 1622–1633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. W. S. Park, S. I. Sung, S. Y. Ahn et al., “Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage,” Cell Transplantation, vol. 25, no. 6, pp. 1131–1144, 2016. View at Publisher · View at Google Scholar · View at Scopus
  137. C. T. Van Velthoven, L. Braccioli, H. L. D. M. Willemen, A. Kavelaars, and C. J. Heijnen, “Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage,” Molecular Therapy, vol. 22, no. 3, pp. 645–654, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. C. T. van Velthoven, A. Kavelaars, F. van Bel, and C. J. Heijnen, “Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration,” Brain, Behavior, and Immunity, vol. 24, no. 3, pp. 387–393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. J. A. Lee, B. I. Kim, C. H. Jo et al., “Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model,” Pediatric Research, vol. 67, no. 1, pp. 42–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. C. T. van Velthoven, A. Kavelaars, F. van Bel, and C. J. Heijnen, “Repeated mesenchymal stem cell treatment after neonatal hypoxia–ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function,” The Journal of Neuroscience, vol. 30, no. 28, pp. 9603–9611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Grade, Y. C. Weng, M. Snapyan, J. Kriz, J. O. Malva, and A. Saghatelyan, “Brain-derived neurotrophic factor promotes vasculature-associated migration of neuronal precursors toward the ischemic striatum,” PLoS One, vol. 8, no. 1, article e55039, 2013. View at Publisher · View at Google Scholar · View at Scopus
  142. C. M. Cotten, A. P. Murtha, R. N. Goldberg et al., “Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy,” The Journal of pediatrics, vol. 164, no. 5, pp. 973–979.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  143. Y. S. Chang, S. Y. Ahn, S. Sung, and W. S. Park, “Stem cell therapy for neonatal disorders: prospects and challenges,” Yonsei Medical Journal, vol. 58, no. 2, pp. 266–271, 2017. View at Publisher · View at Google Scholar · View at Scopus
  144. M. M. Lalu, L. McIntyre, C. Pugliese et al., “Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials,” PLoS One, vol. 7, no. 10, article e47559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. D. Grisafi, M. Pozzobon, A. Dedja et al., “Human amniotic fluid stem cells protect rat lungs exposed to moderate hyperoxia,” Pediatric Pulmonology, vol. 48, no. 11, pp. 1070–1080, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. I. Arutyunyan, A. Elchaninov, A. Makarov, and T. Fatkhudinov, “Umbilical cord as prospective source for mesenchymal stem cell-based therapy,” Stem Cells International, vol. 2016, Article ID 6901286, 17 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Blázquez-Prunera, C. Almeida, and M. Barbosa, “Human bone marrow mesenchymal stem/stromal cells preserve their immunomodulatory and chemotactic properties when expanded in a human plasma derived xeno-free medium,” Stem Cells International, vol. 2017, Article ID 2185351, 12 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  148. M. Krampera, J. Galipeau, Y. Shi, K. Tarte, L. Sensebe, and MSC Committee of the International Society for Cellular Therapy (ISCT), “Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal,” Cytotherapy, vol. 15, no. 9, pp. 1054–1061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. N. Walker, L. Badri, S. Wettlaufer et al., “Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts,” The American Journal of Pathology, vol. 178, no. 6, pp. 2461–2469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. A. M. Hoffman, J. A. Paxson, M. R. Mazan et al., “Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung,” Stem Cells and Development, vol. 20, no. 10, pp. 1779–1792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Franquesa, M. J. Hoogduijn, O. Bestard, and J. M. Grinyó, “Immunomodulatory effect of mesenchymal stem cells on B cells,” Frontiers in Immunology, vol. 3, p. 212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. L. Barkholt, E. Flory, V. Jekerle et al., “Risk of tumorigenicity in mesenchymal stromal cell–based therapies—bridging scientific observations and regulatory viewpoints,” Cytotherapy, vol. 15, no. 7, pp. 753–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. C. Lee, S. A. Mitsialis, M. Aslam et al., “Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension,” Circulation, vol. 126, no. 22, pp. 2601–2611, 2012. View at Publisher · View at Google Scholar · View at Scopus
  154. I. Panfoli, S. Ravera, M. Podestà et al., “Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants,” The FASEB Journal, vol. 30, no. 4, pp. 1416–1424, 2016. View at Publisher · View at Google Scholar · View at Scopus